Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells-Reference-Cited by-同舟云学术

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor‑positive, human epidermal growth factor receptor 2‑positive breast cancer cells

Published:2018-02-08 Issue: Volume: Page:
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Report

Author:

Lim Seung Taek¹,Jeon Ye Won¹,Gwak Hongki¹,Kim Se Young¹,Suh Young Jin¹

Affiliation:

1. Division of Breast and Thyroid Surgical Oncology, Department of Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Gyeonggi 16247, Republic of Korea

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1;Molecular Biology Reports;2024-07-22

2. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit the JAK2/STAT5 signaling via downregulating Bcl-2 and Mcl-1 on BT474 breast cancer cells;2024-04-24

3. Vitamin D and potential effects on cancers: a review;Molecular Biology Reports;2024-01-25

4. Copper-related genes predict prognosis and characteristics of breast cancer;Frontiers in Immunology;2023-04-27

5. Combined treatment with ruxolitinib and MK-2206 inhibits the JAK2/STAT5 and PI3K/AKT pathways via apoptosis in MDA-MB-231 breast cancer cell line;Molecular Biology Reports;2022-11-04